Short-Course Immunotherapy Achieves Five-Year Recurrence-Free Survival in dMMR Colon Cancer

Long-term results from the NICHE-2 study, published in The Lancet, indicate that a short course of immunotherapy administered before surgery prevented disease recurrence for five years in all patients with non-metastatic mismatch repair-deficient (dMMR) colon cancer. All 111 patients in the primary efficacy population remained recurrence-free and alive at their most recent follow-up.